Seagen (Nasdaq: SGEN) has announced latest efficacy and safety results from Part C of a Phase II trial of Adcetris (brentuximab vedotin) alongside nivolumab and standard chemotherapy agents doxorubicin and dacarbazine as a frontline treatment for early-stage classical Hodgkin lymphoma (cHL).
The US biotech, which is set to be acquired by pharma giant Pfizer (NYSE: PFE) for $43 billion, has already won approvals with Adcetris in other cHL indications and cancer types.
In total, the antibody-drug conjugate is approved for seven indications in the USA and five indications in Europe, where Japanese firm Takeda (TYO: 4502) has commercialization rights.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze